Search

everythinglearnresearchcommunity

for

Search:↓

Colchicine can inhibit hair growth by affecting cell activity and protein expression in hair follicles.

Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.

Stilbamidine and hydroxystilbamidine inhibit enzyme release from lysosomes and have effects similar to cortisol and chloroquine.

EBGS reduces platelet adhesion, potentially helping prevent blood clots.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.

Finasteride reduces AML cell growth by inhibiting androgen receptors.

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.

A woman with a drug allergy to anakinra was successfully desensitized, allowing her to continue treatment without allergic reactions.

Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.

These new skin treatments are safer and more effective with minimal side effects.

Kang-ai injection with platinum-based chemotherapy improves tumor response and immune function while reducing side effects in advanced lung cancer.

Anti-Ku-positive patients often have muscle weakness and autophagy plays a key role in their condition.

The cat improved with treatment but had kidney issues from long-term allopurinol use.

KF19418 promotes hair growth similarly to minoxidil but is not better in live mice.

Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.

EGFRi/MEKi treatments cause hair follicles to lose some immune protection, leading to inflammation.

Finasteride poorly inhibits type 1 5AR, affecting its effectiveness.

The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.

JAK inhibitors show promise in treating difficult skin diseases.

The L457(3.43)R mutation in the human lutropin receptor causes increased activity and hormone insensitivity, leading to precocious puberty.

Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.

Five FDA-approved drugs may help block COVID-19 virus entry.

Sorafenib often causes skin side effects, indicating effective cancer treatment.

Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.

JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.

Cladribine has known risks and potential new safety concerns, requiring careful monitoring.

Targeting Hedgehog signaling may help treat ligamentum flavum fibrosis.

JAK inhibitors can effectively regrow hair in alopecia areata patients, but ongoing treatment is needed to maintain results.